Ranking | Patients on maintenance OCS | Item score | Patients not on maintenance OCS | Item score |

National Leads Survey (n=28) | ||||

1 | Reduction of exacerbation rate by 75% over 1 year | 3.4 | Reduction of exacerbation rate by 75% over 1 year | 2.5 |

2 | Reduction of chronic dose of OCS by 50% | 3.4 | Reduction of exacerbation rate by 50% over 1 year | 2.8 |

3 | Stopping chronic maintenance OCS | 3.5 | Reduction of exacerbation rate by 25% over 1 year | 4.8 |

4 | Reduction of exacerbation rate by 50% over 1 year | 4.1 | Reduction in ACQ by 1 at 4/6 months | 5 |

5 | Reduction of exacerbation rate by 25% over 1 year | 6 | Increase in AQLQ by 1 at 4/6 months | 5 |

6 | Increase in AQLQ by 1 at 4/6 months | 6.1 | Reduction in ACQ by 0.5 at 4/6 months | 5.5 |

7 | Reduction in ACQ by 1 at 4/6 months | 6.2 | Increase in AQLQ by 0.5 at 4/6 months | 5.7 |

8 | Reduction in ACQ by 0.5 at 4/6 months | 6.6 | Reduction of chronic dose of ICS by 50% | 6.2 |

9 | Increase in AQLQ by 0.5 at 4/6 months | 6.9 | Improvement of 5% predicted FEV_{1} | 7.6 |

10 | Improvement of 5% predicted FEV_{1} | 8.5 | ||

Experts Broad Survey (n=263) | ||||

1 | Reduction of exacerbation rate by 75% over 1 year | 2.6 | Reduction of exacerbation rate by 75% over 1 year | 1.9 |

2 | Reduction of exacerbation rate by 50% over 1 year | 3.1 | Reduction of exacerbation rate by 50% over 1 year | 3.1 |

3 | Stopping chronic maintenance OCS | 3.5 | Reduction of exacerbation rate by 25% over 1 year | 4.5 |

4 | Reduction of chronic dose of OCS by 50% | 4.1 | Reduction in ACQ by 1 at 4/6 months | 4.6 |

5 | Reduction in ACQ by 1 at 4/6 months | 4.8 | Reduction in ACQ by 0.5 at 4/6 months | 5.2 |

6 | Reduction of exacerbation rate by 25% over 1 year | 5.1 | Reduction of chronic dose of ICS by 50% | 5.6 |

7 | Reduction in ACQ by 0.5 at 4/6 months | 6.3 | Increase in AQLQ by 1 at 4/6 months | 6.3 |

8 | Increase in AQLQ by 1 at 4/6 months | 7.3 | Increase in AQLQ by 0.5 at 4/6 months | 6.8 |

9 | Increase in AQLQ by 0.5 at 4/6 months | 8.5 | Improvement of 5% predicted FEV_{1} | 7.8 |

10 | Improvement of 5% predicted FEV_{1} | 8.9 |

These items are clinical efficacy criteria used in most RCTs to assess effectiveness of biologics in severe asthma. The lower the mean score of the item is, the higher its importance as effectiveness criteria is, according to participants. OCS: oral corticosteroids; AQLQ: Asthma Quality of Life Questionnaire; ACQ: Asthma Control Questionnaire; ICS: inhaled corticosteroids; FEV_{1}: forced expiratory volume in 1 s.